Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan + capecitabine + bevacizumab for advanced extramammary Paget disease
ChiCTR2400086142Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan, capecitabine and bevacizumab in extramammary Paget disease (EMPD), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
irinotecancapecitabinebevacizumab
03
Conditions
extramammary Paget disease (EMPD)
Beyond the preview
Go deeper on ChiCTR2400086142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086142.